1. Efficacy, safety and pharmacokinetics of sugammadex 4 mg kg−1 for reversal of deep neuromuscular blockade in patients with severe renal impairment 
I.F. Panhuizen, S.J.A. Gold, C. Buerkle, M.M.J. Snoeck, N.J.N. Harper, M.J.G.H. Kaspers, M.W. van den Heuvel, M.W. Hollmann 
British Journal of Anaesthesia 
Volume 114, Issue 5, Pages (May 2015)
DOI: /bja/aet586
Copyright © 2015 The Author(s) Terms and Conditions

2. Fig 1
Patient flow through the study, in accordance with CONSORT guidelines. †This patient received sugammadex too early, which also constituted exclusion from the pharmacokinetically (PK) evaluable group; AST, all-subjects-treated; ITT, intent-to-treat.
British Journal of Anaesthesia  , DOI: ( /bja/aet586)
Copyright © 2015 The Author(s) Terms and Conditions

3. Fig 2
Median (range) rocuronium plasma concentration (ng ml−1) vs time (min) after injection of rocuronium and sugammadex, for time points up to 20 min after injection of sugammadex. Inset shows a logarithmic plot of median rocuronium plasma concentration (ng ml−1) vs time (h) for time points up to 48 h after injection of sugammadex†.
British Journal of Anaesthesia  , DOI: ( /bja/aet586)
Copyright © 2015 The Author(s) Terms and Conditions